GAMMAGARD S/D
 |
|
|
Package(a):
SINGLE USE BOTTLE (solution for IV infusion): 1 x 2.5 g.
Dosage(a):
Primary immunodeficiency diseases: Monthly doses of approximately 300-600 mg/kg infused at 3-4 week intervals.
B-cell chronic lymphocytic leukemia: 400 mg/kg every 3-4 weeks.
Idiopathic thrombocytopenic purpura (ITP): 1 g/kg. The need for additional doses can be determined by clinical response and platelet count. Up to three separate doses may be given on alternate days if required. See literature.
Prescribing Restrictions: None
Package(b):
SINGLE USE BOTTLE (solution for IV infusion): 1 x 5 g.
Dosage(b):
Primary immunodeficiency diseases: Monthly doses of approximately 300-600 mg/kg infused at 3-4 week intervals.
B-cell chronic lymphocytic leukemia: 400 mg/kg every 3-4 weeks.
Idiopathic thrombocytopenic purpura (ITP): 1 g/kg. The need for additional doses can be determined by clinical response and platelet count. Up to three separate doses may be given on alternate days if required. See literature.
Prescribing Restrictions: None
Package(c):
SINGLE USE BOTTLE (solution for IV infusion): 1 x 10 g.
Dosage(c):
Primary immunodeficiency diseases: Monthly doses of approximately 300-600 mg/kg infused at 3-4 week intervals.
B-cell chronic lymphocytic leukemia: 400 mg/kg every 3-4 weeks.
Idiopathic thrombocytopenic purpura (ITP): 1 g/kg. The need for additional doses can be determined by clinical response and platelet count. Up to three separate doses may be given on alternate days if required. See literature.
Prescribing Restrictions: None
Indications:
Primary immunodeficiency diseases; B-cell chronic lymphocytic leukemia (CLL)- serum IgG <400 mg/dl; idiopathic thrombocytopenic purpura (ITP).
Contra-Indications:
Patients with selective IgA deficiency where the IgA deficiency is the only abnormality of concern. Patients may experience severe hypersensitivity reactions or anaphylaxis in the setting of detectable IgA levels following infusion of Gammagard S/D, the occurrence of severe hypersensitivity reactions or anaphylaxis under such conditions should prompt consideration of an alternative therapy.
Special Precautions:
Contact distributing company for full details.
Side Effects:
Contact distributing company for full details.
Drug Interactions:
Contact distributing company for full details.
